The Claim
In adults with metabolic dysfunction–associated steatotic liver disease (MASLD), intermittent fasting results in a greater reduction in body weight (mean difference: −1.29 kg) and BMI (mean difference: −0.34 kg/m²) compared to continuous energy restriction over a period of 8 to 52 weeks.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among adults with MASLD, intermittent fasting leads to slightly more weight loss and lower BMI than continuous calorie restriction when followed for 8 to 52 weeks.
See the scientific wording
In adults with metabolic dysfunction–associated steatotic liver disease (MASLD), intermittent fasting leads to a greater reduction in body weight (mean difference: −1.29 kg) and BMI (mean difference: −0.34 kg/m²) compared to continuous energy restriction over 8 to 52 weeks, suggesting it may be a more effective dietary strategy for weight management in this population.
When a person goes without food for periods of time, the body switches from using sugar for energy to burning fat. This causes fat stores to break down, release fatty acids into the blood, and send them to the liver where they are burned for fuel. This process reduces overall fat in the body, leading to lower weight and body mass index.
What the research says
1 studyFor people with fatty liver disease linked to metabolism, eating only during certain hours led to slightly more weight loss and lower BMI than eating fewer calories every day, according to a review of nine studies. This suggests intermittent fasting might help a bit more with weight control.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.